To better understand amyotrophic lateral sclerosis (ALS) and improve patient care, Mitsubishi Tanabe Pharma America (MTPA) is partnering with the ALS/MND Natural History Consortium in collecting real-world data on people with the progressive neurodegenerative disorder. The collaboration will give MTPA access to the consortium’s data repository,…
MTPA joins with ALS/MND patient registry with goal of better care
Last month, a series of health issues bombarded me. They flew in on top of my usual ALS symptoms, causing me to become frustrated and ask, “Has this become my new normal?” But the advice I once received from a TV game show host rescued me — advice that…
Modulo Bio has launched with $8 million in funding and a goal to map the neuroimmune system and develop treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The neuroimmune system involves interactions between the nervous system and the immune system, which normally protects the nervous system…
Early treatment with ropinirole, a medication used to treat Parkinson’s disease, may slow disease progression in amyotrophic lateral sclerosis (ALS) patients, according to recently published data from a Phase 1/2 trial. Patients given the therapy showed slower functional declines and delayed disease progression over those who started treatment…
Mutations in the KIF5A gene, associated with some cases of amyotrophic lateral sclerosis (ALS), may lead to impairments in motor unit recovery that are exacerbated with age, according to a recent study. Motor units — nerve cells involved in movement and the muscle fibers they interact with — showed poor…
Yes, I know, this headline is an obvious conclusion. Yet, based on my dialogue with other ALS patients, as well as my own experience, it’s not always so obvious. In late 2009, I noticed a drop in my left foot. As it progressed, I asked our family doctor what…
As I fed my husband, Todd, his morning breakfast, a charm of yellow finches caught our attention, flitting to and from a mountain ash outside our dining room window. That old tree has brought many moments of joy that are sweet reprieve from the daily challenges of life with…
A final decision by the U.S. Food and Drug Administration (FDA) on whether or not to approve NurOwn for amyotrophic lateral sclerosis (ALS) is now expected no later than Dec. 8. But before that, on Sept. 27, an FDA advisory committee will meet to review the potential benefits…
Bill Nuti, the former CEO and chairman of NCR Corporation, is on a mission to eliminate amyotrophic lateral sclerosis (ALS). Nuti, who stepped away from NCR in 2018 after being diagnosed with ALS, has launched CureALS, a nonprofit that will draw on funding, partnerships, data sourcing, and artificial intelligence…
Every once in a while, I step onto my soapbox (mine has special safety rails) to voice my view about an important issue in the ALS community. This time, I’m here with praise for “ALS and Mental Health,” an article recently published in ALS News Today. In my…
Recent Posts
- New funding backs commercial readiness efforts for ALS therapy
- US lawmakers reintroduce bill to improve access to treatment for ALS
- An emotional dance performance mirrored my life with ALS
- Expanded access program for ALS drug MN-166 at 50% enrollment
- US clinical trials lack diverse representation of ALS patients